WP1 :
* Inclusion criteria:
* De novo type 1 diabetic patient, as per ISPAD criteria;
* Symptoms of hyperglycemia: polyuria-polydipsia-amaigrin +/- Acido ketosis.
* Fasting blood glucose ≥126 mg/dL AND/OR blood glucose ≥200 mg/dL at 120 minutes of an OGTT AND/OR HbA1c ≥6.5% AND/OR a patient with symptoms of hyperglycemia/hyperglycemic crisis (see 8. a. 2.) with random blood glucose ≥200 mg/dL.
Presence in serum of one or more anti-islet autoantibodies (anti-insulin, anti-IA2, anti-GAD65, anti-ZnT8)
* Patients aged between 2 and 30 years
* Minimum weight: 17 kg (for blood samples)
* Male - female patients
* Free, written and oral consent.
* Exclusion criteria:
* Child under 2 years of age.
* Taking treatments interfering with insulin secretion and sensitivity (e.g. sulfonylureas, diazoxide, somatostatin, methylxanthine derivatives, corticosteroids, biguanide, incretins).
* Presence of newly diagnosed (within 1 month) celiac disease (diagnosed on pathological duodenal biopsy) at inclusion.
* Autoimmune/autoinflammatory disease (other than type 1 diabetes) or active malignancy present at inclusion.
* Obesity defined as a BMI with a z-score \>+3 SD.
* Hepatic, renal or adrenal insufficiency.
* History of bone marrow transplantation.
* History of diabetes after hemolytic-uremic syndrome.
* Epileptic patient
* Absence of anti-islet autoantibodies.
* Dysmorphia with suspicion of underlying genetic syndrome.
* Participation in another study in the previous 3 months, with administration of blood derivatives or potentially immunomodulating treatments.
WP2 :
* Inclusion Criteria:
* De novo type 1 diabetic patient, as per ISPAD criteria;
* Symptoms of hyperglycemia: polyuria-polydipsia-amaigrin +/- Acido ketosis.
* Fasting blood glucose ≥126 mg/dL AND/OR blood glucose ≥200 mg/dL at 120 minutes of an OGTT AND/OR HbA1c ≥6.5% AND/OR a patient with symptoms of hyperglycemia/hyperglycemic crisis (see 8. a. 2.) with random blood glucose ≥200 mg/dL.
* Presence in serum of one or more anti-islet autoantibodies (anti-insulin, anti-IA2, anti-GAD65, anti-ZnT8)
* Patients aged between 2 years and 18 years (\<18 years).
* Male - female patients
* Free, written and oral consent.
* Exclusion criteria:
* Child under 2 years of age.
* Taking treatments that interfere with insulin secretion and sensitivity (e.g. sulfonylureas, diazoxide, somatostatin, methylxanthine derivatives, corticosteroids, biguanide, incretins).
* Presence of newly diagnosed (within 1 month) celiac disease (diagnosed on pathological duodenal biopsy) at inclusion.
* Autoimmune/autoinflammatory disease (other than type 1 diabetes) or active malignancy present at inclusion.
* Obesity defined as a BMI with a z-score \>+3 SD.
* Hepatic, renal or adrenal insufficiency.
* History of bone marrow transplantation.
* History of diabetes after hemolytic-uremic syndrome.
* Absence of anti-islet autoantibodies.
* Dysmorphia with suspected underlying genetic syndrome.
* Participation in another study within the previous 3 months with administration of blood derivatives or potentially immunomodulatory treatments.
WP3 :
* Inclusion Criteria:
* Adult older than 18 years.
* Absence of blood marker of diabetes (Absence of antibodies, HbA1C \<6.5%, C-peptide \> 0.18 nmol/L, Fasting blood glucose \< 100 mg/dL, blood glucose at any time \< 200 mg/dL).
* Be a first-degree relative with a patient being followed for diabetes (meeting ISPAD criteria).
* Male - Female
* Free written and oral consent
* Exclusion criteria:
* Taking treatments that interfere with insulin secretion and sensitivity (e.g. sulfonylureas, diazoxide, somatostatin, methylxanthine derivatives, corticosteroids, biguanide, incretins).
* Presence of newly diagnosed (within 1 month) celiac disease (diagnosed on pathological duodenal biopsy) at inclusion.
* Autoimmune/autoinflammatory disease (other than type 1 diabetes) or active malignancy present at inclusion.
* Obesity defined as a BMI with a z-score \>+3 SD.
* Hepatic, renal or adrenal insufficiency.
* History of bone marrow transplantation.
* History of diabetes after hemolytic-uremic syndrome.
* Ischemic cardiomyopathy
* Pregnant participant
* Epileptic patient
WP4 :
* Inclusion Criteria:
Cohort of patients followed for cystic fibrosis:
* Pediatric patient between 2 and 18 years of age.
* Diagnosed with cystic fibrosis with impaired pancreatic endocrine function.
* Presents glucose homeostasis disorders (regular hypo/hyper-glycemia).
* Male - female patient
* Free, written and oral consent
Cohort of patients with (sub)total pancreatectomy:
* Pediatric patients between 2 and 18 years of age.
* Follow-up for total pancreatectomy or caudal pancreatectomy
* Presents disorders of carbohydrate homeostasis (regular hypo-/hyper-glycemia)
* Male - female patient
* Free, written and oral consent
* Exclusion criteria:
* Child under 2 years of age.
* Body weight less than 17 kg.
* Taking treatments that interfere with insulin secretion and sensitivity (e.g. sulfonylureas, diazoxide, somatostatin, methylxanthine derivatives, corticosteroids, biguanide, incretins).
* Presence of newly diagnosed (within 1 month) celiac disease (diagnosed on pathological duodenal biopsy) at inclusion.
* Autoimmune/autoinflammatory disease (other than type 1 diabetes) or active malignancy present at inclusion.
* Obesity defined as a BMI with a z-score \>+3 SD.
* Hepatic, renal or adrenal insufficiency.
* History of bone marrow transplantation.
* History of diabetes after hemolytic-uremic syndrome.
* Dysmorphia with suspected underlying genetic syndrome.
* Participation in another study within the last 3 months, with administration of blood derivatives or potentially immunomodulatory treatments.
WP5 :
* Inclusion Criteria:
* Patient who has undergone insulin testing due to suspected growth hormone deficiency or adrenal insufficiency or hypopituitarism.
* Patients between the ages of 2 years and 18 years (\<18 years).
* Male - female patient.
* Free written and oral consent.
* Exclusion criteria:
* Child under 2 years of age.
* Body weight less than 17 kg.
* Taking treatments that interfere with insulin secretion and sensitivity (e.g. sulfonylureas, diazoxide, somatostatin, methylxanthine derivatives, corticosteroids, biguanide, incretins).
* Presence of newly diagnosed (within 1 month) celiac disease (diagnosed on pathological duodenal biopsy) at inclusion.
* Autoimmune/autoinflammatory disease (other than type 1 diabetes) or active malignancy present at inclusion.
* Obesity defined as a BMI with a z-score \>+3 SD..
* History of bone marrow transplantation.
* History of diabetes after hemolytic-uremic syndrome.
* Participation in another study within the last 3 months, with administration of blood derivatives or potentially immunomodulatory treatments.
WP6 :
* Inclusion Criteria:
* Type 1 diabetic patient, as per ISPAD criteria;
* Symptoms of hyperglycemia: polyuria-polydipsia-amaigrin +/- Acido ketosis.
* Fasting blood glucose ≥126 mg/dL AND/OR blood glucose ≥200 mg/dL at 120 minutes of an OGTT AND/OR HbA1c ≥6.5% AND/OR a patient with symptoms of hyperglycemia/hyperglycemic crisis (see 8. a. 2.) with random blood glucose ≥200 mg/dL.
* Presence in serum of one or more anti-islet autoantibodies (anti-insulin, anti-IA2, anti-GAD65, anti-ZnT8)
* Patients aged between 2 and 18 years (\<18 years).
* Male - female patients
* Free, written and oral consent.
* Exclusion criteria:
* Child under 2 years of age.
* Taking treatments interfering with insulin secretion and sensitivity (e.g. sulfonylureas, diazoxide, somatostatin, methylxanthine derivatives, corticosteroids, biguanide, incretins).
* Autoimmune/autoinflammatory disease (other than type 1 diabetes) or active malignancy present at inclusion.
* Obesity defined as a BMI with a z-score \>+3 SD.
* Hepatic, renal or adrenal insufficiency.
* History of bone marrow transplantation.
* History of diabetes after hemolytic-uremic syndrome.
* Epileptic patient
* Dysmorphia with suspicion of underlying genetic syndrome.
* Participation in another study in the previous 3 months, with administration of blood derivatives or potentially immunomodulating treatments.
WP7 :
* Inclusion Criteria:
* De novo type 1 diabetic patient, as per ISPAD criteria;
* Symptoms of hyperglycemia: polyuria-polydipsia-amaigrin +/- Acido ketosis.
* Fasting blood glucose ≥126 mg/dL AND/OR blood glucose ≥200 mg/dL at 120 minutes of an OGTT AND/OR HbA1c ≥6.5% AND/OR a patient with symptoms of hyperglycemia/hyperglycemic crisis (see 8. a. 2.) with random blood glucose ≥200 mg/dL.
* Presence in serum of one or more anti-islet autoantibodies (anti-insulin, anti-IA2, anti-GAD65, anti-ZnT8)
* Patients aged between 2 and 18 years
* Minimum weight: 17 kg (for blood samples)
* Male - female patients
* Free, written and oral consent.
* Exclusion criteria:
* Child under 2 years of age.
* Taking treatments interfering with insulin secretion and sensitivity (e.g. sulfonylureas, diazoxide, somatostatin, methylxanthine derivatives, corticosteroids, biguanide, incretins).
* Presence of newly diagnosed (within 1 month) celiac disease (diagnosed on pathological duodenal biopsy) at inclusion.
* Autoimmune/autoinflammatory disease (other than type 1 diabetes) or active malignancy present at inclusion.
* Obesity defined as a BMI with a z-score \>+3 SD.
* Hepatic, renal or adrenal insufficiency.
* History of bone marrow transplantation.
* History of diabetes after hemolytic-uremic syndrome.
* Epileptic patient
* Absence of anti-islet autoantibodies.
* Dysmorphia with suspicion of underlying genetic syndrome.
* Participation in another study in the previous 3 months, with administration of blood derivatives or potentially immunomodulating treatments.
